Nuvation Bio Inc. (NUVB) is a Biotechnology company in the Healthcare sector, currently trading at $4.85. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Analyst consensus target is NUVB = $12 (+155.7% upside).
Valuation: NUVB trades at a trailing Price-to-Earnings (P/E) of -7.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.17.
Financials: revenue is $63M, +699%/yr average growth. Net income is $205M (loss), growing at -186%/yr. Net profit margin is -325.3% (negative). Gross margin is 86.6% (+76.5 pp trend).
Balance sheet: total debt is $10M against $306M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 6.95 (strong liquidity). Debt-to-assets is 1.7%. Total assets: $595M.
Analyst outlook: 7 / 9 analysts rate NUVB as buy (78%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).
